Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

215 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Intensification of adjuvant chemotherapy: 5-year results of a randomized trial comparing conventional doxorubicin and cyclophosphamide with high-dose mitoxantrone and cyclophosphamide with filgrastim in operable breast cancer with 10 or more involved axillary nodes.
Fumoleau P, Chauvin F, Namer M, Bugat R, Tubiana-Hulin M, Guastalla JP, Delozier T, Kerbrat P, Devaux Y, Bonneterre J, Filleul A, Clavel M. Fumoleau P, et al. Among authors: kerbrat p. J Clin Oncol. 2001 Feb 1;19(3):612-20. doi: 10.1200/JCO.2001.19.3.612. J Clin Oncol. 2001. PMID: 11157010 Clinical Trial.
Long-term cardiac toxicity after adjuvant epirubicin-based chemotherapy in early breast cancer: French Adjuvant Study Group results.
Fumoleau P, Roché H, Kerbrat P, Bonneterre J, Romestaing P, Fargeot P, Namer M, Monnier A, Montcuquet P, Goudier MJ, Luporsi E; French Adjuvant Study Group. Fumoleau P, et al. Among authors: kerbrat p. Ann Oncol. 2006 Jan;17(1):85-92. doi: 10.1093/annonc/mdj034. Epub 2005 Oct 26. Ann Oncol. 2006. PMID: 16251204 Free article.
Improved disease-free survival with epirubicin-based chemoendocrine adjuvant therapy compared with tamoxifen alone in one to three node-positive, estrogen-receptor-positive, postmenopausal breast cancer patients: results of French Adjuvant Study Group 02 and 07 trials.
Namer M, Fargeot P, Roché H, Campone M, Kerbrat P, Romestaing P, Monnier A, Luporsi E, Montcuquet P, Bonneterre J; French Adjuvant Study Group. Namer M, et al. Among authors: kerbrat p. Ann Oncol. 2006 Jan;17(1):65-73. doi: 10.1093/annonc/mdj022. Ann Oncol. 2006. PMID: 16361531 Free article. Clinical Trial.
Complete hormonal blockade versus epirubicin-based chemotherapy in premenopausal, one to three node-positive, and hormone-receptor positive, early breast cancer patients: 7-year follow-up results of French Adjuvant Study Group 06 randomised trial.
Roché H, Kerbrat P, Bonneterre J, Fargeot P, Fumoleau P, Monnier A, Clavère P, Goudier MJ, Chollet P, Guastalla JP, Serin D. Roché H, et al. Among authors: kerbrat p. Ann Oncol. 2006 Aug;17(8):1221-7. doi: 10.1093/annonc/mdl107. Epub 2006 May 26. Ann Oncol. 2006. PMID: 16731539 Free article. Clinical Trial.
Epirubicin-vinorelbine vs FEC100 for node-positive, early breast cancer: French Adjuvant Study Group 09 trial.
Kerbrat P, Roché H, Bonneterre J, Veyret C, Lortholary A, Monnier A, Fumoleau P, Fargeot P, Namer M, Chollet P, Goudier MJ, Audhuy B, Simon H, Montcuquet P, Eymard JC, Walter S, Clavère P, Guastalla JP; French adjuvant Study Group. Kerbrat P, et al. Br J Cancer. 2007 Jun 4;96(11):1633-8. doi: 10.1038/sj.bjc.6603773. Epub 2007 May 15. Br J Cancer. 2007. PMID: 17505516 Free PMC article. Clinical Trial.
Premenopausal patients with node-positive resectable breast cancer. Preliminary results of a randomised trial comparing 3 adjuvant regimens: FEC 50 x 6 cycles vs FEC 50 x 3 cycles vs FEC 75 x 3 cycles. The French Adjuvant Study Group.
Fumoleau P, Devaux Y, Vo Van ML, Kerbrat P, Fargeot P, Schraub S, Mihura J, Namer M, Mercier M. Fumoleau P, et al. Among authors: kerbrat p. Drugs. 1993;45 Suppl 2:38-45. doi: 10.2165/00003495-199300452-00007. Drugs. 1993. PMID: 7693420 Clinical Trial.
Paclitaxel plus bevacizumab or paclitaxel as first-line treatment for HER2-negative metastatic breast cancer in a multicenter national observational study.
Delaloge S, Pérol D, Courtinard C, Brain E, Asselain B, Bachelot T, Debled M, Dieras V, Campone M, Levy C, Jacot W, Lorgis V, Veyret C, Dalenc F, Ferrero JM, Uwer L, Kerbrat P, Goncalves A, Mouret-Reynier MA, Petit T, Jouannaud C, Vanlemmens L, Chenuc G, Guesmia T, Robain M, Cailliot C. Delaloge S, et al. Among authors: kerbrat p. Ann Oncol. 2016 Sep;27(9):1725-32. doi: 10.1093/annonc/mdw260. Epub 2016 Jul 19. Ann Oncol. 2016. PMID: 27436849 Free article.
Circulating tumour cells and pathological complete response: independent prognostic factors in inflammatory breast cancer in a pooled analysis of two multicentre phase II trials (BEVERLY-1 and -2) of neoadjuvant chemotherapy combined with bevacizumab.
Pierga JY, Bidard FC, Autret A, Petit T, Andre F, Dalenc F, Levy C, Ferrero JM, Romieu G, Bonneterre J, Lerebours F, Bachelot T, Kerbrat P, Campone M, Eymard JC, Mouret-Reynier MA, Gligorov J, Hardy-Bessard AC, Lortholary A, Soulie P, Boher JM, Proudhon C, Charafe-Jaufret E, Lemonnier J, Bertucci F, Viens P. Pierga JY, et al. Among authors: kerbrat p. Ann Oncol. 2017 Jan 1;28(1):103-109. doi: 10.1093/annonc/mdw535. Ann Oncol. 2017. PMID: 28177480 Free article. Clinical Trial.
215 results